Listing 1 - 3 of 3 |
Sort by
|
Choose an application
Fabry disease is an X-linked inborn error of metabolism wherein deficiency of a lysosomal enzyme results in systemic deposition of glycosphingolipids. Storage deposition, and hence pathological disease, occurs preferentially in renal glomerular and tubular epithelial cells, myocardial cells, heart valve fibrocytes, neurons of dorsal root ganglia, and in endothelial smooth muscle cells of blood vessels. Thus, Fabry disease is a multi-system disorder, albeit with considerable phenotypic heterogeneity in onset and in severity; however, it is progressive, exhibits extensive morbidity, and is life-threatening. Within the past two decades, there has been a radical change in the natural course Fabry disease by virtue of the availability of specific enzyme replacement therapy. Moreover, there has been a concerted effort to better understand the underlying pathology and equally to identify patients prior to the onset of irreversible end-organ damage. It is to be hoped that the future for patients with Fabry disease can be viewed with greater, albeit guarded, optimism. This state-of-the-art textbook attempts to bridge the span of pre-clinical studies, clinical finding, and management options in a readable but comprehensive manner for the medical practitioner as well as the interested non-medical reader.
Lysosomal storage diseases -- Pathogenesis. --- Lysosomal storage diseases -- Treatment. --- Lysosomal storage diseases. --- Lysosomal storage diseases --- Proteins --- Sphingolipidoses --- Cytoplasmic Vesicles --- Metabolic Phenomena --- Genetic Diseases, X-Linked --- Lysosomal Storage Diseases, Nervous System --- Organelles --- Genetic Diseases, Inborn --- Lipidoses --- Phenomena and Processes --- Fabry Disease --- Metabolism --- Lysosomes --- Lysosomal Storage Diseases --- Brain Diseases, Metabolic, Inborn --- Lipid Metabolism, Inborn Errors --- Congenital, Hereditary, and Neonatal Diseases and Abnormalities --- Lipid Metabolism Disorders --- Cytoplasmic Structures --- Metabolism, Inborn Errors --- Brain Diseases, Metabolic --- Diseases --- Cytoplasm --- Metabolic Diseases --- Nutritional and Metabolic Diseases --- Intracellular Space --- Brain Diseases --- Central Nervous System Diseases --- Cellular Structures --- Nervous System Diseases --- Cells --- Anatomy --- Medicine --- Health & Biological Sciences --- Metabolic & Nutritional Diseases --- Disorders --- Disorders. --- Protein metabolism disorders --- Cell storage disorders --- Lysosomal disorders --- Lysosomal enzyme disorders --- Storage diseases, Lysosomal --- Medicine. --- Human genetics. --- Metabolic diseases. --- Medicine & Public Health. --- Metabolic Diseases. --- Human Genetics. --- Metabolism, Inborn errors of --- Genetics --- Heredity, Human --- Human biology --- Physical anthropology --- Disorders of metabolism --- Metabolic diseases --- Metabolic disorders --- Metabolism, Disorders of
Choose an application
Fabry disease is an X-linked inborn error of metabolism wherein deficiency of a lysosomal enzyme results in systemic deposition of glycosphingolipids. Storage deposition, and hence pathological disease, occurs preferentially in renal glomerular and tubular epithelial cells, myocardial cells, heart valve fibrocytes, neurons of dorsal root ganglia, and in endothelial smooth muscle cells of blood vessels. Thus, Fabry disease is a multi-system disorder, albeit with considerable phenotypic heterogeneity in onset and in severity; however, it is progressive, exhibits extensive morbidity, and is life-threatening. Within the past two decades, there has been a radical change in the natural course Fabry disease by virtue of the availability of specific enzyme replacement therapy. Moreover, there has been a concerted effort to better understand the underlying pathology and equally to identify patients prior to the onset of irreversible end-organ damage. It is to be hoped that the future for patients with Fabry disease can be viewed with greater, albeit guarded, optimism. This state-of-the-art textbook attempts to bridge the span of pre-clinical studies, clinical finding, and management options in a readable but comprehensive manner for the medical practitioner as well as the interested non-medical reader.
Human genetics --- Pathology of the metabolism --- medische genetica --- genetica --- metabolische ziekten
Choose an application
Fabry disease is an X-linked inborn error of metabolism wherein deficiency of a lysosomal enzyme results in systemic deposition of glycosphingolipids. Storage deposition, and hence pathological disease, occurs preferentially in renal glomerular and tubular epithelial cells, myocardial cells, heart valve fibrocytes, neurons of dorsal root ganglia, and in endothelial smooth muscle cells of blood vessels. Thus, Fabry disease is a multi-system disorder, albeit with considerable phenotypic heterogeneity in onset and in severity; however, it is progressive, exhibits extensive morbidity, and is life-threatening. Within the past two decades, there has been a radical change in the natural course Fabry disease by virtue of the availability of specific enzyme replacement therapy. Moreover, there has been a concerted effort to better understand the underlying pathology and equally to identify patients prior to the onset of irreversible end-organ damage. It is to be hoped that the future for patients with Fabry disease can be viewed with greater, albeit guarded, optimism. This state-of-the-art textbook attempts to bridge the span of pre-clinical studies, clinical finding, and management options in a readable but comprehensive manner for the medical practitioner as well as the interested non-medical reader.
Medicine & Public Health. --- Metabolic Diseases. --- Human Genetics. --- Medicine. --- Human genetics. --- Metabolic diseases. --- Médecine --- Génétique humaine --- Lysosomal storage diseases. --- Proteins --- Fabry Disease. --- Lysosomes --- Metabolism --- Disorders. --- metabolism. --- Metabolism.
Listing 1 - 3 of 3 |
Sort by
|